Key result
Angiotensin II receptor blockers (ARBs) showed a comparable risk of myocardial infarction to other antihypertensive drugs or placebo (OR 1.008; 95% CI 0.950-1.069).
Why the study?
Do angiotensin II receptor blockers (ARBs) affect the risk of myocardial infarction compared with conventional treatment or placebo in patients with cardiovascular risk factors or disease?
Meta-Analysis (n=108,909)
Yes
Do angiotensin II receptor blockers (ARBs) affect the risk of myocardial infarction compared with conventional treatment or placebo in patients with cardiovascular risk factors or disease?
Odds Ratio: 1.008 (95% CI 0.95–1.069)
Absolute Event Rate: 4.46% vs 4.43%
This meta-analysis demonstrates that ARBs have a comparable risk of myocardial infarction to other antihypertensive drugs or placebo, addressing prior concerns about a potential 'ARB MI paradox'.
No takes yet. Share an insight, caveat, or question.
ARBs carry no excess MI risk versus other agents or placebo; challenges the ARB-MI paradox and reinforces safety in high-risk patients.
Volpe et al. (2009) conducted a meta-analysis in hypertension, high cardiovascular risk, stroke, coronary disease, renal disease and heart failure (n=108,909). Angiotensin II receptor blockers (ARBs) vs. other drugs or conventional therapies (placebo) was evaluated on myocardial infarction (MI) (OR 1.008, 95% CI 0.950-1.069). Angiotensin II receptor blockers (ARBs) showed a comparable risk of myocardial infarction to other antihypertensive drugs or placebo (OR 1.008; 95% CI 0.950-1.069).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: